GlassScriptPhysician profile
Melissa Mccool Senn
NPI 1033735204
$8,144.33
in general payments reported to CMS, 2019-2025
35 companies · $4,226 in 2025
The $4,226 reported for 2025 was more than what 98% of Physician Assistant providers received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $31.12 · 2022: $303 · 2023: $952 · 2024: $2,632 · 2025: $4,226.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,158 · Education: $652.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,157.85 |
| Education | $652.09 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,073.30 | 2023-2025 | Dupixent |
| Abbvie INC. | $955.43 | 2023-2025 | |
| Ucb, INC. | $843.54 | 2023-2025 | Bimzelx |
| Janssen Biotech, INC. | $775.22 | 2023-2025 | Tremfya, Stelara, Simponi Aria |
| Sun Pharmaceutical Industries INC. | $566.64 | 2024-2025 | |
| Amgen INC. | $455.82 | 2023-2025 | Otezla, Otezla, Evenity |
| Novartis Pharmaceuticals Corporation | $429.30 | 2023-2025 | |
| Incyte Corporation | $392.04 | 2024-2025 | Opzelura, Opzelura |
| Genzyme Corporation | $389.55 | 2024-2025 | |
| Galderma Laboratories, L.P. | $283.16 | 2024-2025 | Nemluvio |
| Boehringer Ingelheim Pharmaceuticals, INC. | $234.20 | 2023-2025 | Spevigo |
| Lilly USA, LLC | $201.17 | 2023-2025 | Taltz, Ebglyss, Mounjaro |
| Baxter Healthcare | $192.62 | 2022 | |
| Dermavant Sciences, INC. | $185.31 | 2024 | Vtama |
| Leo Pharma INC. | $182.97 | 2024-2025 | Adbry, Spevigo |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $149.45 | 2023-2025 | |
| Organon LLC | $136.09 | 2025 | Vtama, Nexplanon |
| Arcutis Biotherapeutics, INC. | $95.09 | 2025 | Zoryve |
| Sanofi-Aventis U.S. LLC | $72.00 | 2023 | |
| Verrica Pharmaceuticals INC. | $66.59 | 2024-2025 | Ycanth |
| Tela Bio, INC. | $58.38 | 2022 | |
| Astrazeneca Pharmaceuticals LP | $55.73 | 2023 | Breztri, Farxiga |
| Allergan, INC. | $54.90 | 2021-2022 | |
| E.R. Squibb & Sons, L.L.C. | $54.85 | 2024-2025 | Sotyktu |
| Biofrontera INC. | $37.26 | 2023-2024 | Ameluz, Xepi, Bf-Rhodoled |
| Smith+Nephew, INC. | $28.49 | 2021-2022 | |
| Exact Sciences Corporation | $28.03 | 2023 | Cologuard Collection Kit |
| Cipher Pharmaceuticals US LLC | $26.02 | 2025 | Spinosad, Natroba |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $22.96 | 2023 | Jublia, Arazlo, Duobrii |
| Novo Nordisk INC | $21.18 | 2023 | Wegovy |
| Bayer Healthcare Pharmaceuticals INC. | $17.06 | 2023 | |
| Paratek Pharmaceuticals, INC. | $16.10 | 2024 | Nuzyra |
| Botanix Sb INC | $15.05 | 2025 | Sofdra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.89 | 2023 | Xifaxan, Trulance |
| Otsuka America Pharmaceutical, INC. | $13.94 | 2023 | Rexulti |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Melissa Senn listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.